of the disease. i think the people who would benefit are those who are newly diagnosed with early stage alzheimer s disease. the patients who took part, in 1a countries around the world, they had early alzheimer s. now, that comes with problems, because in order to benefit from the drug, you have to have a confirmatory diagnosis that you have a particular rogue protein in your brain called amyloid, which builds up, which lecanamab clears. at the moment, only one or 2% of alzheimer s patients have those confirmatory tests, either through specialist scans all lumbar punctures, which then you can analyse the cerebrospinalfluid. if lecanamab is licensed in the uk, and wider around the world next year, it will take a
and our medical editor, fergus walsh can join us now. you underline how significant it is, put it into context as to who could have access to the drug in the uk, who could benefit? the have access to the drug in the uk, who could benefit? have access to the drug in the uk, who could benefit? the people who would benefit who could benefit? the people who would benefit are who could benefit? the people who would benefit are those who could benefit? the people who would benefit are those who - who could benefit? the people who would benefit are those who are - would benefit are those who are newly diagnosed with early stage alzheimer s disease. the patients who took part, in 1a countries around the world, they had early alzheimer s. now, that comes with problems, because in order to benefit from the drug, you have to have a confirmatory diagnosis that you have a particular rogue protein in your brain, called amyloid, which builds up, which lecanamab clears. at the moment, only 1% o
confirmatory diagnosis that you have a particular rogue protein in your brain which fills up which the drug clears. at the moment, only one or 2% of alzheimer s patients have those confirmatory tests, either through specialist scans, or number punctures, which then you can analyse the spinal fluid. if the drug is licensed in the uk, and wider around the world next year, it will take a complete overhaul and a restructuring of dementia services before it would be able to be widely used. david cox was diagnosed with early onset alzheimer s around ten years ago when we was 65. hejoins me with his wife, heather. you are very welcome, thank you for joining us today. david, i want to ask you what it felt like to be diagnosed at such a relatively early
/PRNewswire/ The "Influenza Diagnostics Market by Product (Test Kits, Instruments), Test Type (Traditional (RIDT, Viral Culture, Serological), Molecular.
/PRNewswire/ The "Influenza Diagnostics Market by Product (Test Kits, Instruments), Test Type (Traditional (RIDT, Viral Culture, Serological), Molecular.